Celcuity reports positive Phase 3 results for gedatolisib in PIK3CA-mutant breast cancer
On May 4, 2026 Celcuity announced that its experimental drug gedatolisib achieved success in two treatment regimens for patients whose tumors carry PIK3CA mutations, according to data from its ongoing Phase 3 trial.
The trial results indicate that the drug met its primary endpoints in this genetically defined subgroup, reinforcing the therapeutic potential of targeting the PI3K pathway in breast cancer.
In related biotech news Odyssey Therapeutics disclosed plans to raise approximately $205 million through an initial public offering, while Latus Bio reported an extension of its Series A clinical endpoints, suggesting continued activity in the sector.
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Celcuity's breast cancer win; Odyssey plans $205M IPO”
read at Endpoints ↗
comments(0)
5-min edit window · permanent after that